

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Atty. Docket No: 053466/0296

In re patent application of

KISHIMOTO, TADAMITSU et al

Serial No. 09/756,125

Filed: January 9, 2001



For: CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING IL-6 ANTAGONIST AS
EFFECTIVE COMPONENT

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

RECEIVED
SEP 25 2001
TECH CENTER 1600/2900

Sir:

In connection with a Sequence Listing submitted concurrently
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37
C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the
attached computer readable copy of the Sequence Listing, submitted in
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;
and


3. all statements made herein of their own knowledge are
true and that all statements made on information and belief are believed to
be true; and further, that these statements were made with the knowledge
that willful false statements and the like so made are punishable by fine
or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/756,125

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Aug. 14, 2001
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021